Healthcare, Pharma, Medical Device etc.
Category
Japan, United states of America, Europe, Rest of World
Geographic Coverage
Not Available
Video URL
Not Available
Sale price (USD)
Not Available
Non-exclusive license price (USD)
Not Available
Exclusive license price (USD)
Not Available
Non-exclusive license royalty rate %
Availability
Patent family
Number of members in the patent family
Assignee(s) / Patent owner(s)
To see the additional information details please login and subscribe to a Premium account.

NGAL/Kidney disease

Patent Granted n the case of acute kidney injury (AKI), NGAL is secreted in high levels into the blood and urine within 2 hours of injury.[9] Because NGAL is protease resistant and small, the protein is easily excreted and detected in the urine.[10] NGAL levels in patients with AKI have been associated with the severity of their prognosis and can be used as a biomarker for AKI[9] NGAL can also be used as an early diagnosis for procedures such as chronic kidney disease, contrast induced nephropathy, and kidney transplant.

BROKER APPLY submit an inquiry
photo To see the additional information details please login and subscribe to a Plus or Premium account.